Mother-to-child transmission of HIV in a community-based antiretroviral clinic in South Africa

South African Medical Journal

Volumn 100, Issue 12, 2010, Pages 827-831

  Fitzgerald, Felicity C ^a   Bekker, Linda Gail ^a   Kaplan, Richard ^a   Myer, Landon ^a   Lawn, Stephen D ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COMMUNITY CARE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT MORTALITY; INFECTION PREVENTION; INFECTION RISK; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PROGNOSIS; SOUTH AFRICA; SPONTANEOUS ABORTION; STILLBIRTH; TREATMENT DURATION; TUBERCULOSIS; VERTICAL TRANSMISSION; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 78650140064     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.4045     Document Type: Article

References (21)

1. UNAIDS. Progress Report on Declaration of Commitment on HIV and AIDS. Republic of South Africa. Reporting Period: January 2006 - December 2007. http://data.unaids.org/pub/Report/2008/south_africa_2008_country_progress_report_en.pdf (accessed 14 October 2008).
2. Health Systems Trust. The District Health Barometer - Year 2006/07. http://www.hst.org.za/publications/717 (accessed 5 November 2008).
3. Policy and Guidelines for the Implementation of the PMTCT Programme. Pretoria: National Department of Health. http://www.doh.gov.za/docs/policy/pmtct-f.html (accessed 10 October 2008).
4. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of Human Immunodeficiency Virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 team. N Engl J Med 1999;341(6):385-393.
5. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999;341(6):394-402.
6. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992;339(8800):1007-1012.
7. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Sydnr 2002;29:484-494.
8. Shapiro D, Tuomala R, Pollack H, et al. Mother-to-child HIV transmission risk according to antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2004 [Abstract 99].
9. World Health Organization. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach. 2006 revision. http://www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf (accessed 10 October 2008).
10. World Health Organization. Rapid Advice: Use of Antiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. http://www.who.int/hiv/pub/mtct/rapid_advice_mtct.pdf (accessed 30 November 2009).
11. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of motherto- child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 2008;22(8):973-981.
12. European Collaborative Study, Patel D, Cortina-Borja M, Thorne C, Newell ML. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis 2007;44(12):1647-1656.
13. Warszawski J, Tubiana R, Le Chenadec J, et al. ANRS French Perinatal Cohort. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 2008;22(2):289-299.
14. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Cote d'Ivoire. AIDS 2008;22(14):1815-1820.
15. Black V, Hoffman RM, Sugar CA, et al. Safety and efficacy of initiating highly active antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr 2008;3:276-281.
16. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J 2006;96(4):315-320.
17. South African Government Information. HIV & AIDS and STI strategic plan for South Africa, 2007-2011. http://www.info.gov.za/otherdocs/2007/aidsplan2007/executive_summary.pdf (accessed 31 October 2008).
18. Stinson K, Boulle A, Coetzee D, Abrams E, Myer L. Initiation of highly active antiretroviral therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health. In press.
19. Newell ML, Coovadia H, Cortina-Borja M, et al. Lancet 2004;364(9441):1236-1243.
20. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among pregnant women referred to a community clinic for antiretroviral treatment. AIDS 2008;22(13):1679-1681.
21. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to followup in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007;12(5):687-694.